More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$161561682
EPS
0.12
P/E ratio
14.9
Price to sales
1.65
Dividend yield
--
Beta
2.117588
Previous close
$2.01
Today's open
$2
Day's range
$1.95 - $2.05
52 week range
$1.95 - $7.12
show more
CEO
Rob Fried
Employees
117
Headquarters
Los Angeles, CA
Exchange
NASDAQ Capital Market
Shares outstanding
79196903
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Niagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on Aging
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Aging--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it will support the Sixth Annual Longevity Summit taking place from December 9 to 10, 2026, at the Buck Institute for Research on Aging in Novato, California. The Summit, themed “The Future of Medicine: Eliminating Diseases of Aging,” convenes researchers, investors and government organizations to dis.
Business Wire • Nov 16, 2026

Niagen Bioscience Expands HSA/FSA Payment Option for the Pharmaceutical-Grade Niagen™ At-Home Injection Kit through Niagen™ Plus
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has partnered with Truemed to provide qualified customers the option to purchase the Niagen™ At-Home Injection Kit using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds, now available through its Niagen™ Plus telehealth platform. Qualified customers may use HSA/FSA funds.
Business Wire • Nov 12, 2026

Niagen Bioscience Announces Participation in Upcoming Investor Conferences
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: A.G.P. Virtual Consumer Showcase Virtual showcase offering consumer company management teams a platform to share their story with the investment community Location: Virtual Date: November 11 - 12, 2026 Format: Fireside chat.
Business Wire • Nov 9, 2026

Niagen Bioscience, Inc. (NAGE) Q3 2026 Earnings Call Transcript
Niagen Bioscience, Inc. (NAGE) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its operational updates and financial results for the third quarter of 2026. Third Quarter 2026 Financial and Business Highlights Total net sales of $27.2 million, including $23.3 million from Tru Niagen®. Direct to consumer sales on the Company's website grew by 13% year-over-year. Gross margin of 62.
Business Wire • Nov 4, 2026

Niagen Bioscience (NAGE) Reports Q3 Loss, Lags Revenue Estimates
Niagen Bioscience (NAGE) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline
Niagen Bioscience (NAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 28, 2026

Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of the clinician-directed, prescription-only pharmaceutical-grade Niagen™ At-Home Injection Kit, featuring the Company's first ready-to-inject liquid formulation with Niagen™ (patented nicotinamide riboside, or NR), the most studied, high-quality NAD+ precursor brand available, now availabl.
Business Wire • Oct 22, 2026

Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Beauty--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line, led by the Niagen® Skincare Innovation Lab. The inaugural product in this new category is Niagen NanoCloud™, the first dermatologist-tested topical product powered by Niagen® (patented nicotinamide riboside, or NR.
Business Wire • Oct 20, 2026

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2026. The company will report the financial results in a press release after the close of regular stock market trading hours on Wednesda.
Business Wire • Oct 15, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Niagen Bioscience Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.